FDA approves generic versions of osteoporosis drug

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic version of a drug for treating and preventing osteoporosis in women after menopause, the agency said Monday.



The FDA announced the approval of ibandronate tablets in the 150-mg strength made by Apotex, Orchid Healthcare and Mylan Pharmaceuticals. Genentech makes the branded version of the drug.



"Men as well as women are affected by osteoporosis, a disease that can be prevented and treated," FDA Office of Pharmaceutical Science deputy director Keith Webber said. "For people who must manage their health conditions over time, it is important to have affordable treatment options."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.